1. Home
  2. SPXX vs LUNG Comparison

SPXX vs LUNG Comparison

Compare SPXX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen S&P 500 Dynamic Overwrite Fund

SPXX

Nuveen S&P 500 Dynamic Overwrite Fund

HOLD

Current Price

$18.02

Market Cap

331.3M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.53

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPXX
LUNG
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
331.3M
57.9M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
SPXX
LUNG
Price
$18.02
$1.53
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
220.4K
393.9K
Earning Date
01-01-0001
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$15.78
$1.13
52 Week High
$18.53
$3.88

Technical Indicators

Market Signals
Indicator
SPXX
LUNG
Relative Strength Index (RSI) 51.64 53.50
Support Level $17.65 $1.36
Resistance Level $18.15 $1.64
Average True Range (ATR) 0.18 0.12
MACD -0.02 0.01
Stochastic Oscillator 45.41 57.78

Price Performance

Historical Comparison
SPXX
LUNG

About SPXX Nuveen S&P 500 Dynamic Overwrite Fund

Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35% to 75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: